Wednesday, 4 January 2017

New Report Covers Tanzania Midstream Oil and Gas Industry to 2021

Tanzania Midstream Oil and Gas Industry Outlook to 2021: Market Forecasts for Oil Storage, Pipelines and Gas Processing is a new market research publication announced by Reportstack. This report is a comprehensive report on midstream oil and gas industry in Tanzania. The report provides oil consumption and imports from 2000 to 2020. The report also provides natural gas production and consumption from 2000 to 2020. It also provides historic gas reserves for the period 2000 to 2015. Further, the report provides details such as name, type, operational status and operator for all active and planned (new build) oil storage terminals, major trunk pipelines and gas processing plants in Tanzania till 2021. Further, the report also offers recent developments in the country’s midstream sector.
Scope
- Historic and forecast of oil data related to consumption and imports for the period 2000-2020
- Historic and forecast of natural gas data related to production and consumption for the period 2000-2020, and reserves for the period 2000-2015
- Updated information related to all active and planned oil storage terminals, major trunk pipelines and gas processing plants in the country, including operator and equity details
- Key mergers and acquisitions, partnerships, private equity and initial public offerings in the country’s midstream oil and gas industry, where available
- Latest developments related to midstream oil and gas industry in the country
Reasons to buy
- Gain a strong understanding of the country’s energy sector and midstream oil and gas industry
- Facilitate decision making on the basis of strong historic and forecast of production, reserves and capacity data
- Assess your competitor’s major oil storage terminals, major trunk pipelines and gas processing plants in the country
- Analyze the latest developments related to the country’s midstream oil and gas industry
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

In-Depth Research on Methanol Industry in India to 2020

Methanol Industry Outlook in India to 2020 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants is a new market research publication announced by Reportstack. This report provides in-depth coverage of India’s Methanol industry and presents major market trends. The report covers India’s Methanol plants and presents installed capacity by production process and technology. It also gives historical and forecast market size, demand and production forecasts, end-use demand details, price trends, trade balance data, and company shares of the country’s leading Methanol producers to provide comprehensive coverage of all parameters of the Methanol industry.
Scope
- Methanol industry supply scenario in India from 2006 to 2020, comprising plant capacity growth and installed plant capacity by production process and technology
- Detailed information of all active plants and planned Methanol projects in India with capacity forecasts to 2020 and additional details such as production process, technology, operator and equity
- Methanol industry market dynamics in India from 2006 to 2020, consisting of market size, demand and production outlook, demand by end-use sector, and average prices
- Trade balance data from 2006 to 2020, including import and export data and net exports and imports as a percentage of demand
- Company snapshots, including company overview, business description and information on current and upcoming Methanol plants
- Company capacity shares for key Methanol producers
Reasons to buy
- Obtain up-to-date information on India’s Methanol industry
- Benefit from the advanced insights and analysis
- Identify the macro and microeconomic trends affecting the industry
- Understand the market positioning of the country’s Methanol producers
- Learn about opportunities in the Methanol industry
- Develop market-entry and market-expansion strategies
- Benchmark your operations and strategies against those of major companies
Companies Mentioned
Deepak Fertilisers and Petrochemicals Corporation Limited Rashtriya Chemicals and Fertilizers Limited Gujarat State Fertilizers & Chemicals Limited
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

Market Research Outlook on Methanol Industry in China to 2020

Methanol Industry Outlook in China to 2020 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants is a new market research publication announced by Reportstack. This report provides in-depth coverage of China’s Methanol industry and presents major market trends. The report covers China’s Methanol plants and presents installed capacity by production process and technology. It also gives historical and forecast market size, demand and production forecasts, end-use demand details, price trends, trade balance data, and company shares of the country’s leading Methanol producers to provide comprehensive coverage of all parameters of the Methanol industry.
Scope
- Methanol industry supply scenario in China from 2006 to 2020, comprising plant capacity growth and installed plant capacity by production process and technology
- Detailed information of all active plants and planned Methanol projects in China with capacity forecasts to 2020 and additional details such as production process, technology, operator and equity
- Methanol industry market dynamics in China from 2006 to 2020, consisting of market size, demand and production outlook, demand by end-use sector, and average prices
- Trade balance data from 2006 to 2020, including import and export data and net exports and imports as a percentage of demand
- Company snapshots, including company overview, business description and information on current and upcoming Methanol plants
- Company capacity shares for key Methanol producers
Reasons to buy
- Obtain up-to-date information on China’s Methanol industry
- Benefit from the advanced insights and analysis
- Identify the macro and microeconomic trends affecting the industry
- Understand the market positioning of the country’s Methanol producers
- Learn about opportunities in the Methanol industry
- Develop market-entry and market-expansion strategies
- Benchmark your operations and strategies against those of major companies
Companies Mentioned
Yankuang Group Co., Ltd. Shenhua Ningxia Coal Industry Group Co., Ltd China Shenhua Energy Company Limited
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

In-Depth Market Analysis On Methanol Industry in Germany to 2020

Methanol Industry Outlook in Germany to 2020 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants is a new market research publication announced by Reportstack. This report provides in-depth coverage of Germany’s Methanol industry and presents major market trends. The report covers Germany’s Methanol plants and presents installed capacity by production process and technology. It also gives historical and forecast market size, demand and production forecasts, end-use demand details, price trends, trade balance data, and company shares of the country’s leading Methanol producers to provide comprehensive coverage of all parameters of the Methanol industry.
Scope
- Methanol industry supply scenario in Germany from 2006 to 2020, comprising plant capacity growth and installed plant capacity by production process and technology
- Detailed information of all active plants and planned Methanol projects in Germany with capacity forecasts to 2020 and additional details such as production process, technology, operator and equity
- Methanol industry market dynamics in Germany from 2006 to 2020, consisting of market size, demand and production outlook, demand by end-use sector, and average prices
- Trade balance data from 2006 to 2020, including import and export data and net exports and imports as a percentage of demand
- Company snapshots, including company overview, business description and information on current and upcoming Methanol plants
- Company capacity shares for key Methanol producers
Reasons to buy
- Obtain up-to-date information on Germany’s Methanol industry
- Benefit from the advanced insights and analysis
- Identify the macro and microeconomic trends affecting the industry
- Understand the market positioning of the country’s Methanol producers
- Learn about opportunities in the Methanol industry
- Develop market-entry and market-expansion strategies
- Benchmark your operations and strategies against those of major companies
Companies Mentioned
Total S.A. BASF SE Royal Dutch Shell plc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

New Research Explores on EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025 is a new market research publication announced by Reportstack. Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Invasive breast cancer in this analysis is defined as ICD-10 codes C50.0-50.9, while non-invasive DCIS breast cancer is defined as ICD-10 code D05.1; both types of breast cancer are based on country-specific, nationally representative sources. Uniform diagnostic criteria are used for all segmentations across the 8MM, where a breast biopsy was used to confirm cases of breast cancer. In addition, comparable staging criteria by the AJCC (American Joint Committee on Cancer) and UICC (Union for International Cancer Control) were applied across all 8MM.
The epidemiologists forecast that the diagnosed incident cases of invasive breast cancer (not including DCIS) in the 8MM for women will grow by an Annual Growth Rate (AGR) of 1.94% over the next 10 years, from 795,114 cases in 2015 to 949,161 cases in 2025. In 2015, the 60-69 year age group had the highest number of diagnosed incident cases of invasive breast cancer, contributing 195,701 (24.61%) cases of the total in the 8MM. Overall, the majority of diagnosed incident cases of breast cancer occurred in ages 40 years and older, accounting for 95.48% of all cases in the 8MM in 2015. The 8MM will see an increase in five-year diagnosed prevalent cases throughout the forecast period at an AGR of 2.39%, with 3,549,784 cases in 2015 and 4,399,243 in 2025. For HER2 status of diagnosed incident cases of invasive breast cancer in the 8MM throughout the forecast period, 17.53% of cases were HER2+, 68.07% were HER2-/HR+, and 14.40% were TN.
The epidemiologists utilized comprehensive, country-specific data from national breast cancer registries and peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident and five-year diagnosed prevalent cases of breast cancer. In this analysis, The epidemiologists provide detailed, clinically relevant segmentations for diagnosed incident cases of breast cancer.
Scope
- The Breast Cancer EpiCast Report provides an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). This report includes a forecast of non-invasive ductal carcinoma in situ (DCIS) breast cancer cases segmented by HER2 status. In addition, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of invasive breast cancer in women segmented by age (18 to 85 years and older) and HER2 status (HER2+/hormone receptor [HR]+, HER2+/HR-, HER2-/HR+, and HER2-/HR- triple negative [TN]). HER2+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and site of metastasis; HER2-/HR+ invasive breast cancer cases are further segmented by stage at diagnosis, menopausal status, and biomarker expression; and TN invasive breast cancer cases are further segmented by stage at diagnosis and BRCA expression.
- The breast cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy
The Breast Cancer EpiCast report will allow you to - 
- Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
- Quantify patient populations in the global breast cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for breast cancer therapeutics in each of the markets covered.
- Compare patient population potentials by HER2 status, menopausal status, and biomarker expression
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

Market Overview on EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025 is a new market research publication announced by Reportstack. Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV can cause both acute and chronic hepatitis infection. According to the World Health Organization (WHO), an estimated 130-150 million individuals worldwide are affected with chronic HCV and about 500,000 people died of HCV-related conditions, including liver cirrhosis and hepatocellular carcinoma (HCC), in 2010 (Lozano et al., 2012; WHO, 2015).
In the 9MM, The epidemiologists forecast that the anti-HCV+ total prevalent cases will increase from 19,842,780 total prevalent cases in 2015 to 20,886,113 total prevalent cases in 2025, at an Annual Growth Rate (AGR) of 0.53%. China will have the highest number of anti-HCV+ total prevalent cases among the 9MM throughout the forecast period, while Germany will have the lowest number of anti-HCV+ total prevalent cases. In the 9MM, The epidemiologists forecast that the HCV RNA+ total prevalent cases will increase from 9,932,624 total prevalent cases in 2015, to 10,399,601 total prevalent cases in 2025, at an AGR of 0.47%. In the 9MM, The epidemiologists forecast that the anti-HCV+ diagnosed prevalent cases will increase from 5,681,205 diagnosed prevalent cases in 2015, to 5,944,944 diagnosed prevalent cases in 2025, at an AGR of 0.46%. In the 9MM, The epidemiologists forecast that the HCV RNA+ diagnosed prevalent cases will increase from 2,992,433 diagnosed prevalent cases in 2015, to 3,115,901 diagnosed prevalent cases in 2025, at an AGR of 0.41%.
This forecast is supported by historical data from government reports and national studies published in peer-reviewed journals. All data used for the analysis were country-specific. All studies that were used confirmed anti-HCV+ and HCV RNA+ total prevalent cases through laboratory diagnostic tests. Also, The epidemiologists did not include studies that oversampled the high-risk population groups, such as IDUs, as we believe this would inflate the anti-HCV+ total prevalence. Furthermore, additional segmentation of the anti-HCV+ diagnosed prevalent cases by age, sex, and liver cirrhosis status will provide the most refined and granular forecast results. The forecast methodology was also consistent across the 9MM, thereby allowing for a meaningful comparison of the forecast numbers in these markets.
Scope
- The Hepatitis C Virus (HCV) EpiCast Report provides an overview of the risk factors and global trends of HCV in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China). It includes a 10-year epidemiological forecast of the anti-HCV+ and HCV RNA+ total prevalent cases (including diagnosed and undiagnosed), which are segmented by sex and age. The anti-HCV+ total prevalent cases are further segmented by genotype, human immunodeficiency virus (HIV) comorbidity, and hepatitis B virus (HBV) comorbidity among the 9MM. Additionally, the report also includes anti-HCV+ and HCV RNA+ diagnosed prevalent cases, which are also segmented by sex and age. The anti-HCV+ diagnosed prevalent cases are segmented by liver cirrhosis status.
- The HCV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
Reasons to buy
The HCV EpiCast report will allow you to - 
- Develop business strategies by understanding the trends shaping and driving the global HCV market.
- Quantify patient populations in the global HCV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCV therapeutics in each of the markets covered.
- Identify the percentage of HCV prevalent cases by genotype, HIV and HBV comorbidity, and liver cirrhosis status.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

Detailed Study of the EpiCast Report: Immune Thrombocytopenia (ITP) - Epidemiology Forecast to 2025

EpiCast Report: Immune Thrombocytopenia (ITP) - Epidemiology Forecast to 2025 is a new market research publication announced by Reportstack. Immune thrombocytopenia (ITP) is an autoimmune syndrome involving the antibody- and cell-mediated destruction of platelets and the suppression of platelet production; this increases an affected individual’s susceptibility to bleeding. More specifically, the destruction and suppression of platelets are due to B cell (and sometimes CD8+ T cell) autoimmune reactions directed against circulating platelets and megakaryocytes. An ITP diagnosis is made when the platelet count is between 100 and 150 x 109/L. About 80% of all ITP cases are considered to be idiopathic, also known as primary ITP. The remaining 20% of ITP cases occur as a component of another clinically evident disorder, such as hepatitis C or systemic lupus erythematosus, or drug exposure; these cases are categorized as secondary ITP.
The epidemiologists selected nationally representative population-based studies, peer-reviewed journals, and registries (for example: GPRD, JIDIC) that used Read codes which are cross-referenced with ICD-9 and ICD-10 (D69.3) codes to diagnose ITP. ITP was defined as having platelet levels between 100-150 x 109/L.
In the 7MM, the diagnosed prevalent cases of primary and secondary ITP will increase from 359,208 cases in 2015 to 384,780 cases in 2025 at an annual growth rate (AGR) of 0.71%. The 5EU will have the highest number of diagnosed prevalent cases throughout the forecast period with 179,350 cases in 2015 and 191,229 cases in 2025, while Japan will have the lowest number of diagnosed prevalent cases with 24,468 in 2015 and 24,479 in 2025.
In the 7MM, the diagnosed incident cases of primary and secondary ITP will increase from 33,136 cases in 2015 to 35,364 cases in 2025, at an AGR of 0.67%.
Scope
- The Immune Thrombocytopenia (ITP) EpiCast Report provides an overview of the risk factors and global trends of NSCLC in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of ITP segmented by type (primary and secondary), sex, and age.
- The ITP epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The ITP EpiCast report will allow you to - 
- Develop business strategies by understanding the trends shaping and driving the global ITP market.
- Quantify patient populations in the global ITP market to improve product design, pricing, and launch plans.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###